The company said 677 of its GPS Cancer commercial tests were ordered in Q1 2018, up from 606 in Q4 2017.
CEO Patrick Soon-Shiong said that GPS Cancer test revenues rose threefold year over year during Q4, and 606 GPS tests were ordered, up from 325 a year ago.
The company has also developed two liquid biopsy cancer test, Liquid GPS Core for DNA and Liquid GPS Expression for RNA.
UCSF researchers will use NantHealth's GPS Cancer molecular analysis test in their molecular profiling study of metastatic breast cancer.
The company fell short of the consensus Wall Street revenue estimate, while its net loss for the quarter also widened.
Politico examines sales of Patrick Soon-Shiong's genetic test to institutions with clinicians with ties to his companies.
Asia Genomics will distribute NantHealth's cancer molecular profiling service in Singapore, Malaysia, Thailand, Vietnam, and the Philippines.
The restructuring and job cuts are expected to save the firm more than $70 million annually.
A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.
Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.
A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.
In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more